Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

By continuing you agree to the terms and privacy policy.

Welcome — one more step

News Plus opens the cross-newsroom layer — who covered a story, who didn’t, and how each one worded it.

  • Ask Duki without the monthly limit — answers from the coverage, with sources
  • Save articles, synced between the web and the app
  • Every Not Everywhere story, no daily limit
  • How each newsroom worded the same event
  • Filing timeline and coverage breakdown
  • The whole archive, searchable
  • Unlimited newsroom, topic and people follows
  • The daily brief by email, in English or Hebrew

Eligible new subscribers get 7 days free, then $34.99 each year. Renews automatically until cancelled. Cancel any time in your account. Subscription terms.

Your subscription also unlocks the app.

Download on theApp StoreGet it onGoogle Play

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Live Terminal
Economy · Full coverage

Israeli Pharma Firm Rafa Gets Buy Rating, 45% Upside Target

How 2 Israeli newsrooms covered this story — translated into English and compared side by side.

Unrated 2

By בן פלמון

First reported by Ice · 1 hour ago

What happened

Investment firm Leader initiated coverage of Rafa Laboratories with a buy rating and a NIS 24 price target, citing strong growth potential in its pharmaceutical and biodéfense segments. The analysis highlights upcoming product launches, strategic acquisitions, and expansion of production capacity as key drivers for future profitability.

  • 01Rafa Laboratories stock initiated with buy rating and NIS 24 target.
  • 02Firm projects significant profit and revenue growth through 2027.
  • 03Growth driven by new drug launches and biodéfense segment expansion.
  • 04Acquisition of Exceed contributes significantly to company valuation.
  • 05Biodéfense segment to see increased auto-injector production capacity.
  • 06New products for bleeding and opioid overdose treatment in development.

Summary translated & synthesized from the sources below by baba. Read each original for the full report.

In this story
OrganizationsRafa Laboratories, Leader, Exceed, BARDA, US Food and Drug Administration
PlacesIsrael, United States, Central Europe, Eastern Europe

Full coverage · 2 outlets

The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.

BizportalUnrated · Hebrew1 hour ago
Israeli Pharma Firm Rafa Gets Buy Rating, 45% Upside Target
IceUnrated · Hebrew1 hour ago
Israeli Drugmaker Rafa Labs Receives Buy Recommendation Amid Growth Prospects

Related stories

Rafa Pharma Raises Half a Billion Shekels in Share Sale Led by Pimi FundJul 14, 2026Pimi Fund Pushes Rafa Pharma IPO Despite 30% Valuation CutJul 10, 2026Rafa Laboratories Workers Declare Labor Dispute Less Than a Month After IPOAug 3, 2026Rafa and Abisror Lower Valuations in Tel Aviv IPOs Amid Weak Market ConditionsJul 12, 2026Rafael CEO: State Owes Billions, Hurting Company and IPO PlansAug 30, 2026Rafael Chairman Calls for Public Listing to Compete with Global Defense Firms on Talent and FundingJul 17, 2026